Abeona Therapeutics Inc. (NASDAQ:ABEO) SVP Sells $102,128.08 in Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) SVP Brendan M. O'malley sold 17,428 shares of the stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total value of $102,128.08. Following the sale, the senior vice president owned 360,817 shares of the company's stock, valued at approximately $2,114,387.62. This represents a 4.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Abeona Therapeutics Stock Down 1.9%

NASDAQ ABEO traded down $0.11 during trading on Friday, hitting $5.74. 774,254 shares of the company traded hands, compared to its average volume of 701,305. Abeona Therapeutics Inc. has a 12 month low of $3.93 and a 12 month high of $7.32. The business has a fifty day simple moving average of $6.01 and a 200 day simple moving average of $5.57. The company has a current ratio of 4.90, a quick ratio of 4.90 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $293.66 million, a P/E ratio of -4.52 and a beta of 1.51.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.11. As a group, sell-side analysts predict that Abeona Therapeutics Inc. will post -1.16 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ABEO. Wall Street Zen lowered Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. Oppenheimer started coverage on Abeona Therapeutics in a report on Monday, June 2nd. They set an "outperform" rating and a $19.00 price objective for the company. Stifel Nicolaus cut their target price on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Alliance Global Partners restated a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. Finally, HC Wainwright raised their target price on Abeona Therapeutics from $15.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $19.25.

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ABEO. Adage Capital Partners GP L.L.C. grew its position in shares of Abeona Therapeutics by 20.1% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company's stock valued at $21,736,000 after purchasing an additional 652,366 shares during the last quarter. Western Standard LLC grew its position in shares of Abeona Therapeutics by 22.8% in the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company's stock valued at $11,610,000 after purchasing an additional 386,321 shares during the last quarter. Jane Street Group LLC grew its position in shares of Abeona Therapeutics by 894.8% in the fourth quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company's stock valued at $732,000 after purchasing an additional 118,262 shares during the last quarter. 683 Capital Management LLC grew its position in shares of Abeona Therapeutics by 17.3% in the fourth quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company's stock valued at $4,411,000 after purchasing an additional 116,845 shares during the last quarter. Finally, Newtyn Management LLC grew its position in shares of Abeona Therapeutics by 26.3% in the first quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company's stock valued at $2,285,000 after purchasing an additional 100,000 shares during the last quarter. 80.56% of the stock is owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.